Clinical Trials Directory

Trials / Completed

CompletedNCT07042204

Effectiveness of E-prf Alone and in Combination With Bioactive Glass Nanoparticles in Grade II Furcation Defects

Effectiveness of Extended Platelet-Rich Fibrin (ePRF) Alone and in Combination With Bioactive Glass Nanoparticles in the Treatment of Grade II Furcation Defects

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Merna Nasser Mohamed Mostafa Ibrahim Elnahas · Academic / Other
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically.

Detailed description

A total of 30 grade II furcation defects will be randomly divided into three groups as follows: Group I: 10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone. Group II: 10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF). Group III: 10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.

Conditions

Interventions

TypeNameDescription
PROCEDUREGroup I (extended platelet-rich fibrin)mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group
PROCEDUREGroup II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)
PROCEDUREGroup III (bioactive glass nanoparticles and covered by a collagen membrane)bioactive glass nanoparticles and covered by a collagen membrane

Timeline

Start date
2024-01-03
Primary completion
2025-06-03
Completion
2025-08-03
First posted
2025-06-27
Last updated
2026-01-13

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07042204. Inclusion in this directory is not an endorsement.